Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    NCT00955435
Previous Study | Return to List | Next Study

Study of Blood and Urine Samples in Patients With Newly Diagnosed Localized Prostate Cancer Treated With Hormone Therapy and Radiation Therapy. ICORG 06-15

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT00955435
Recruitment Status : Active, not recruiting
First Posted : August 10, 2009
Last Update Posted : February 18, 2021
Sponsor:
Information provided by (Responsible Party):
Cancer Trials Ireland

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:

RATIONALE: Studying samples of blood and urine from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment.

PURPOSE: This clinical trial is studying blood and urine samples in patients with newly diagnosed localized prostate cancer treated with hormone therapy and radiation therapy.


Condition or disease Intervention/treatment
Prostate Cancer Other: Non-interventional Genetic: Protein expression analysis Genetic: Proteomic profiling Other: Laboratory biomarker analysis

Detailed Description:

OBJECTIVES:

  • Detect changes in serum and urine proteomic profiles that predict outcome in patients with newly diagnosed localized prostate cancer treated with hormonal therapy and radiotherapy.
  • Identify prognostic and biochemical markers of early disease progression in patients treated with this regimen.
  • Identify unique protein expression and temporal alterations, in these profiles, that facilitate understanding of the factors predicting relapse or toxicity.
  • Identify molecular signatures that allow identification of targets for therapeutic intervention.

OUTLINE: This is a multicenter study.

Patients receive induction hormones* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy (per standard treatment). Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.NOTE: * Patients receiving short-term hormonal treatment for 4-8 months are eligible to participate in the trial.

Blood and urine samples are collected at baseline, and periodically during and after induction therapy for proteomic analysis.

After completion of study therapy, patients are followed up periodically for 5 years and yearly thereafter for the duration of the trial.

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Actual Enrollment : 60 participants
Observational Model: Cohort
Time Perspective: Prospective
Official Title: Proteomic Analysis of the Combined Hormonal Therapy and Radiation Therapy for Localized Prostate Cancer
Actual Study Start Date : February 2006

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Intervention Details:
  • Other: Non-interventional
    Patients receive induction hormones* (bicalutimide and releasing-hormone agonist) for approximately 4 months prior to starting radiotherapy per standard treatment. Patients then receive radiotherapy consisting of 74 Gy up to a maximum of 81 Gy to the prostate gland per standard treatment.
  • Genetic: Protein expression analysis
  • Genetic: Proteomic profiling
  • Other: Laboratory biomarker analysis

Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Changes in serum and urine proteomic profiles [ Time Frame: Ongoing until patient progression ]
  2. Prognostic and biochemical markers of early disease progression [ Time Frame: Ongoing until patient progression ]
  3. Protein expression and temporal alterations [ Time Frame: Ongoing until patient progression ]
  4. Molecular targets [ Time Frame: Ongoing until patient progression ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   Male
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Patients diagnosed with localised prostate cancer who will receive radiation therapy plus hormonal therapy, for 4 - 8 months, are eligible for the trial. Patients will be eligible to participate in the trial provided they have not received prior therapy for their prostate cancer. It is planned that 60 patients will participate in the research study. All patients will receive approx 4 months of induction hormone therapy (LHRH agonist and Bicalutamide) prior to starting radiotherapy treatment.
Criteria

Inclusion criteria:

  1. Age 18 years or over.
  2. Histologically confirmed invasive adenocarcinoma of the prostate (by TURP or TRUS).
  3. Localised prostate cancer with a Gleason score 7
  4. Short term hormonal treatment 4-8 months
  5. Performance status of KPS ≥ 60 / WHO 0-2
  6. Absence of distant metastases

Exclusion criteria:

  1. The patient has previously received treatment for prostate cancer other than TURP/ TRUS
  2. The patient has had a bilateral orchidectomy
  3. The patient has previously received hormonal treatment for prostate cancer
  4. Evidence of any other significant clinical disorder or laboratory finding that makes it undesirable for the patient to participate in the trial. In the opinion of the investigator, any evidence of severe or uncontrolled systematic disease (e.g. unstable or uncompensated respiratory, cardiac, hepatic or renal disease
  5. The patient has or had other co-existing malignancies within the past 5 years other than non- melanoma skin cancer
  6. Treatment with non-approved or investigational drug within 30 days before day one of the trial
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00955435


Locations
Layout table for location information
Ireland
Beacon Hospital
Dublin, Ireland, 18
Saint Luke's Radiation Oncology Network
Dublin, Ireland, 6
Sponsors and Collaborators
Cancer Trials Ireland
Investigators
Layout table for investigator information
Principal Investigator: John Gerard Armstrong, MD, MB, MRCPI Saint Luke's Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Cancer Trials Ireland
ClinicalTrials.gov Identifier: NCT00955435    
Other Study ID Numbers: CTRIAL-IE (ICORG) 06-15
CTRIAL-IE (ICORG) 06-15
EU-20921
First Posted: August 10, 2009    Key Record Dates
Last Update Posted: February 18, 2021
Last Verified: February 2021
Keywords provided by Cancer Trials Ireland:
adenocarcinoma of the prostate
stage I prostate cancer
stage IIB prostate cancer
stage IIA prostate cancer
stage III prostate cancer
Additional relevant MeSH terms:
Layout table for MeSH terms
Prostatic Neoplasms
Genital Neoplasms, Male
Urogenital Neoplasms
 Neoplasms by Site
Neoplasms
Prostatic Diseases